Voyager Therapeutics, Inc. (VYGR) Financial Statements
Voyager Therapeutics, Inc. (VYGR) reported trailing twelve-month revenue of $34.5M (down 19.1% year on year) and net income of -$107.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$121.4M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VYGRVoyager Therapeutics, Inc.Follow VYGR — free
—
Price chart with a free account
- Market cap
- 107.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.3 | 14.2 | 10.1 | 7.6 | 104.4 | 171.1 | 37.4 | 40.9 | 250.0 | 80.0 | 40.4 | 34.5 | |
| Research & development | 27.7 | 42.2 | 62.3 | 64.9 | 119.7 | 108.8 | 73.8 | 60.8 | 92.2 | 127.4 | 134.7 | 118.5 | |
| Operating income | -20.3 | -41.3 | -71.9 | -91.1 | -51.7 | 27.4 | -73.6 | -50.8 | 122.0 | -83.3 | -131.8 | -117.2 | |
| Pre-tax income | -29.7 | -40.1 | -70.7 | -88.5 | -43.6 | 36.7 | -71.2 | -46.4 | 133.7 | -64.3 | -119.6 | -107.6 | |
| Income tax | — | 0.1 | — | -0.2 | — | — | — | 0.0 | 1.4 | 0.7 | 0.1 | 0.1 | |
| Net income | -29.7 | -40.2 | -70.7 | -88.3 | -43.6 | 36.7 | -71.2 | -46.4 | 132.3 | -65.0 | -119.7 | -107.7 | |
| Diluted EPS ($) | 9.14 | -1.59 | -2.64 | -2.75 | -1.21 | 0.98 | -1.89 | -1.21 | 2.97 | -1.13 | -2.04 | -1.81 | |
| Diluted shares (mn) | — | — | — | — | — | 37.3 | 37.7 | 38.4 | 44.6 | 57.7 | 58.7 | — |
USD millions · SEC XBRL
Voyager Therapeutics, Inc. — questions
- What is Voyager Therapeutics, Inc.'s revenue?
- $34.5M over the twelve months to 2026-06-30, down 19.1% year on year, from its 10-Q and 10-K filings.
- What is Voyager Therapeutics, Inc.'s net income?
- -$107.7M over the twelve months to 2026-06-30.
- What is Voyager Therapeutics, Inc.'s free cash flow?
- -$121.4M over the twelve months to 2026-06-30.
- What are Voyager Therapeutics, Inc.'s diluted earnings per share?
- $-1.81 over the twelve months to 2026-06-30.
Every figure on this page comes from Voyager Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.